Squarepoint
RAPP

Squarepoint’s Rapport Therapeutics RAPP Stock Holding History

Squarepoint’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,859
Closed -$238K – 5122
2025
Q4 		$238K Buy
+7,859
New +$218K ﹤0.01% 3767
2024
Q3 		– Sell
-16,345
Closed -$380K – 4793
2024
Q2 		$380K Buy
+16,345
New +$378K ﹤0.01% 3277

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Squarepoint's RAPP Position: Q1 2026 in Review

Squarepoint sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 7,859 shares — an estimated $238K sold.

Squarepoint first reported a position in RAPP in Q2 2024 and held it in 2 quarters. The position peaked at $380K in Q2 2024. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Squarepoint reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 7,859 Rapport Therapeutics shares in Q1 2026, an estimated $238K.
  • Squarepoint first reported a position in Rapport Therapeutics in Q2 2024 and held it in 2 quarters.
  • Squarepoint's Rapport Therapeutics position peaked at $380K in Q2 2024.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.